Treatment of acute host-versus-graft reaction in patients after allogeneic hematopoietic cell transplantation with multipotent mesenchymal stromal cells from a bone marrow donor


如何引用文章

全文:

详细

Aim. To evaluate the efficiency of administration of multipotent mesenchymal stromal cells obtained from a bone marrow donor for the treatment of an acute host-versus-graft reaction (HVGR) resistant to therapy with glucocorticosteroids (GCS). Subjects and methods. The experience in treating 6 patients with GCS-resistant acute HVGR following allogeneic hematopoietic stem cell transplantation is given. The patients were intravenously injected cultured multipotent mesenchymal stromal cells (MMSC) in a dose of 106 per kg body weight. Results. Four weeks after MMSC administration, a complete or partial response was obtained in 3 cases; clinical improvement was noted in 2; one patient showed no response. MMSC therapy proved to be effective in 5 of the 6 cases with acute HVGR resistant to GCS therapy. Conclusion. MMSC therapy turned out to be effective in case of acute HVGR resistant to GCS therapy.

全文:

Лечение острой реакции "трансплантат против хозяина" у больных после трансплантации аллогенных гемопоэтических клеток мультипотентными мезенхимальными стромальными клетками из костного мозга донора. - Резюме. Цель исследования. Оценка эффективности введения мультипотентных мезенхимальных стромальных клеток, полученных из костного мозга донора, для лечения острой реакции "трансплантат против хозяина" (РТПХ), резистентной к терапии глюкокортикостероидами (ГКС). Материалы и методы. Представлен опыт лечения 6 больных с резистентной к ГКС острой РТПХ после трансплантации аллогенных гемопоэтических стволовых клеток. Больным вводили внутривенно культивированные мультипотентные мезенхимальные стромальные клетки (ММСК) в дозе 106 на 1 кг массы тела. Результаты. Через 4 нед после введения ММСК в 3 случаях получен полный или частичный ответ, в 2 отмечено клиническое улучшение, у одного пациента ответ не получен. Терапия ММСК оказалась эффективной в 5 случаях из 6 при возникновении острой РТПХ, резистентной к терапии ГКС. Заключение. Терапия ММСК оказалась эффективной при возникновении острой РТПХ, резистентной к лечению ГКС.
×

参考

  1. Mohty M., Apperley J.F. Long-term physiological side effects after allogeneic bone marrow transplantation. Hematology Am Soc Hematol Educ Program 2010; 2010: 229-236.
  2. Majumdar M.K., Keane-Moore M. et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 2003; 10: 228-241.
  3. Svinareva D.A., Shipunova I.N., Ol'shanskaia I. et al. The basic properties of mesenchymal stromal cells from the donor bone marrow: superficial markers. Ter Arkh 2010; 82: 52-56.
  4. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 2008; 36: 733-741.
  5. Djouad F., Charbonnier L.M., Bouffi C. et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032.
  6. Jiang X.X., Zhang Y., Liu B. et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126.
  7. Ramasamy R., Fazekasova H., Lam E.W. et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83: 71-76.
  8. Zhang W., Ge W., Li C. et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13: 263-271.
  9. Krampera M., Glennie S., Dyson J. et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729.
  10. Le Blanc K., Rasmusson I., Gotherstrom C. et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004; 60: 307-315.
  11. Glennie S., Soeiro I., Dyson P.J. et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827.
  12. Plumas J., Chaperot L., Richard M.J. et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597-1604.
  13. Corcione A., Benvenuto F., Ferretti E. et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372.
  14. Deng W., Han Q., Liao L. et al. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 2005; 24: 458-463.
  15. Le Blanc K., Rasmusson I., Sundberg B. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441.
  16. Muller I., Kordowich S., Holzwarth C. et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 25-32.
  17. Fang D., Seo B.M., Liu Y. et al. Transplantation of mesenchymal stem cells is an optimal approach for plastic surgery. Stem Cells 2007; 25: 1021-1028.
  18. Ringden O., Uzunel M., Rasmusson I. et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397.
  19. Lazarus H.M., Koc O.N., Devine S.M. et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-398.
  20. Ringden O., Uzunel M., Rasmusson I. et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397.
  21. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 2008; 36: 733-741.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2012

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##